Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2004 2
2005 2
2008 2
2009 1
2010 1
2011 1
2012 1
2013 1
2014 1
2015 1
2016 2
2017 2
2018 1
2019 1
2020 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

17 results

Results by year

Filters applied: . Clear all
Page 1
Maintenance with lanreotide in small-cell lung cancer expressing somatostatine receptors: A multicenter, randomized, phase 3 trial.
Santo A, Pilotto S, Galetta D, Grossi F, Fasola G, Romano G, Bonanno L, Bearz A, Papi M, Roca E, Catino A, Follador A, Rijavec E, Genova C, Petrillo P, Favaretto A, Giannone L, Milella M, Tortora G, Giannarelli D, Bria E; Italian association FONICAP (Operative National Interdisciplinary Force against Lung Cancer). Santo A, et al. Among authors: papi m. Lung Cancer. 2019 Aug;134:121-126. doi: 10.1016/j.lungcan.2019.06.011. Epub 2019 Jun 11. Lung Cancer. 2019. PMID: 31319970 Clinical Trial.
Staging of breast cancer: new recommended standard procedure.
Ravaioli A, Pasini G, Polselli A, Papi M, Tassinari D, Arcangeli V, Milandri C, Amadori D, Bravi M, Rossi D, Fattori PP, Pasquini E, Panzini I. Ravaioli A, et al. Among authors: papi m. Breast Cancer Res Treat. 2002 Mar;72(1):53-60. doi: 10.1023/a:1014900600815. Breast Cancer Res Treat. 2002. PMID: 12000220
Impact of TP53 Mutations on Outcome in EGFR-Mutated Patients Treated with First-Line Tyrosine Kinase Inhibitors.
Canale M, Petracci E, Delmonte A, Chiadini E, Dazzi C, Papi M, Capelli L, Casanova C, De Luigi N, Mariotti M, Gamboni A, Chiari R, Bennati C, Calistri D, Ludovini V, Crinò L, Amadori D, Ulivi P. Canale M, et al. Among authors: papi m. Clin Cancer Res. 2017 May 1;23(9):2195-2202. doi: 10.1158/1078-0432.CCR-16-0966. Epub 2016 Oct 25. Clin Cancer Res. 2017. PMID: 27780855
Frequency of actionable alterations in epidermal growth factor receptor (EGFR) wild type non-small cell lung cancer: experience of the Wide Catchment Area of Romagna (AVR).
Chiadini E, Canale M, Delmonte A, Dazzi C, Casanova C, Capelli L, Mariotti M, Papi M, Gamboni A, Puccetti M, Bravaccini S, Dubini A, Calistri D, Crinò L, Ulivi P. Chiadini E, et al. Among authors: papi m. J Thorac Dis. 2018 Aug;10(8):4858-4864. doi: 10.21037/jtd.2018.07.22. J Thorac Dis. 2018. PMID: 30233859 Free PMC article.
Nonsquamous, Non-Small-Cell Lung Cancer Patients Who Carry a Double Mutation of EGFR, EML4-ALK or KRAS: Frequency, Clinical-Pathological Characteristics, and Response to Therapy.
Ulivi P, Chiadini E, Dazzi C, Dubini A, Costantini M, Medri L, Puccetti M, Capelli L, Calistri D, Verlicchi A, Gamboni A, Papi M, Mariotti M, De Luigi N, Scarpi E, Bravaccini S, Turolla GM, Amadori D, Crinò L, Delmonte A. Ulivi P, et al. Among authors: papi m. Clin Lung Cancer. 2016 Sep;17(5):384-390. doi: 10.1016/j.cllc.2015.11.004. Epub 2015 Dec 1. Clin Lung Cancer. 2016. PMID: 26712101
17 results